Microviable obtiene dos proyectos financiados en la convocatoria europea CanSERV enfocada en “Reaching and Understanding of Cancer”.
Estamos orgullosos de anunciar que nuestra propuesta titulada “Exploring the relationships between anti-PD1 responders and gut microbiota: intervention with a highly purified microbiota as immunotherapy adjuvant” ha sido seleccionada para ser financiada por la Unión Europea en la convocatoria de proyectos de @canSERV!
Las dos propuestas de Microviable financiadas son para validar nuestro lead candidate MVT-201 en dos tipos de cáncer:
- We are excited to work together with Fundaçao GIMM- Gulbenkian Institute for Molecular Medicine to carry out a preclinical model of CRC using MVT-201 as adjuvant for anti-PD1 immunotherapy.
- We are excited to work together with the Istituto Romagnolo per lo Studio dei Tumori “Dino Amatori” to perform a preclinical model of lung cancer using MVT-201 as adjuvant for anti-PD1 immunotherapy.
This service will help us move towards understanding how microbiome can overcome some barriers of immunotherapy and the key players involved in this phenomenon.
Support from canSERV enables cancer researchers to advance their research by providing access to a broad range of high-quality research services, accelerating impactful research across Europe.
Muy orgullosos de nuestro equipo y en especial de nuestro Director Técnico David Ríos, PhD que ha liderado estos proyectos!
🔗 Learn more about canSERV: https://www.canserv.eu/
#CancerResearch #EUCancerMission #canSERV_EU”
